Search
01/10/2025
ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress
Provencio, M, Aguiar, D, Antoñanzas, M, Areses, MC, Azkárate, A, Barba, A, Bernabé, R, Blanco, R, Borregon, M, Campos, B, Coves, J, De Castro, J, Domènech, M, Domine, M, Campelo, RG, Gozálvez, CL, Huidobro, G, Insa, A, Juan-Vidal, O, Castro, RL, Martínez-Marti, A, Medina, S, Moreno, MA, Nadal, E, Olivares, A, Reguart, N, Sala, MA, Medina, K, Vilà, L, Massuti, B. ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study-Trial in Progress. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study
Grohé, C, Wu, YL, Tsuboi, M, Majem, M, John, T, Bolanos, A, Taylor, R, Sandelin, M, Herbst, RS. Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2025
From fibro/adipogenic progenitors to adipocytes: Understanding adipogenesis in muscle degeneration for disease modulation
Villalobos, E, Mehra, P, Diaz-Manera, J. From fibro/adipogenic progenitors to adipocytes: Understanding adipogenesis in muscle degeneration for disease modulation. JOURNAL OF PHYSIOLOGY-LONDON. 2025; 603(19)DOI:10.1113/JP288924. PMID:40846464. IF:4.400(Q1/1D).
01/10/2025
INTERACTION OF PREVIOUS MAJOR ADVERSE CARDIOVASCULAR EVENTS, ANTITHROMBOTICS, AND STATINS ON OUTCOMES IN INTRACEREBRAL HEMORRHAGE
Prats-Sanchez, L, Lambea-Gil, A, Martí-Fàbregas, J, Ezcurra, G, Guasch, M, Fernandez-Vidal, JM, Renom, PC, Martínez-Domeño, A, Ramos-Pachón, A, Hic-Cat, I. INTERACTION OF PREVIOUS MAJOR ADVERSE CARDIOVASCULAR EVENTS, ANTITHROMBOTICS, AND STATINS ON OUTCOMES IN INTRACEREBRAL HEMORRHAGE. International Journal of Stroke. 2025; 20DOI:. PMID:. IF:8.700(Q1/1D).